Company: AEMD
Filing Date: 2025-04-08
Form Type: PRE 14A
Source: 0001683168-25-002332
Chunk: 31

Company: AETHLON MEDICAL INC
Filing Date: 2025-04-08
Form: PRE 14A
Chunk 31
---
 (6) months from the date of issuances
and have a term of exercise of five and one half (5.5) years from the date of issuance and (ii) a reduction of the exercise price of the
Existing Warrants to $0.3736 per share, representing the closing price on March 14, 2025, but only with respect to a cash exercise under
the Existing Warrants (as reduced from the previous respective exercise price as set forth in the Existing Warrants).

The closing took place on March 17, 2025. Gross
proceeds to the Company from the exercise of the Existing Warrants was approximately $2,316,320 million, prior to deducting closing costs
and placement agent fees as further described below. We intend to use the net proceeds from the offering for working capital and general
corporate purposes. As a result of the Holder exercising the Existing Warrants, the Company issued an aggregate of 6,200,000 shares of
its common stock. The shares underlying the Existing Warrants have all been registered on Form S-1 registration statement (Registration
Number 333-278188).

Based on the Inducement
Warrant exercise price of $0.3736, (and not adjusted pursuant to the Reset of Exercise Price provision discussed below), the Holder may
be issued up to a maximum of 12,400,000 shares of common stock under the Inducement Warrants. However, holder is subject to a beneficial
ownership limitation of 4.99% limiting the issuance of such shares. The common shares issuable under the Inducement Warrants are also
subject to adjustment for stock splits, reclassifications, subdivisions and similar adjustments.

We agreed to file
a resale registration statement registering the shares underlying the Inducement Warrants (“Resale Registration Statement”)
within ninety (90) days of the date of the Agreement and to use commercially reasonable best efforts to cause the Resale Registration
Statement to be effective on or prior to the 150th calendar day after the date of the Agreement. Subject to the terms of the Agreement,
we will be required to pay certain liquidated damages if the shares underlying the Inducement Warrants are not filed within the ninety
(90) period, as more fully described in the Agreement.

We further agreed
that until sixty (60) days after the closing date of the warrant exercise, it will not (other than in connection with limited enumerated
exceptions) issue, enter